Key result
Sotatercept beats placebo in treating PAH while maintaining a fair safety profile.
Why the study?
This study aimed to evaluate the safety and efficacy of the new fusion protein sotatercept in pulmonary arterial hypertension.
Does sotatercept improve safety and efficacy parameters compared to placebo in patients with pulmonary arterial hypertension?
Meta-Analysis
Does sotatercept improve safety and efficacy parameters compared to placebo in patients with pulmonary arterial hypertension?
p-value: p=0.02
Sotatercept demonstrates efficacy and a fair safety profile compared to placebo in the treatment of pulmonary arterial hypertension.
Supports sotatercept adoption in PAH; confirms and extends prior trial findings via meta-analysis.
INTRODUCTION: Pulmonary arterial hypertension (PAH) has responded favorably to the new fusion protein named sotatercept. This study aimed to evaluate the safety and efficacy of sotatercept in PAH. METHODS: The online databases like PubMed/Medline, Cochrane Library, and ClinicalTrials.gov were searched until 15 September 2024 for studies comparing sotatercept to placebo using keywords such as "sotatercept, pulmonary arterial hypertension, and 'fusion protein.' RESULTS: = 0.02]. CONCLUSION: This study demonstrates that sotatercept is more effective than placebo in treating PAH and has a fair safety profile.ClinicalTrial.gov Identifier numbers: NCT04576988 and NCT03496207 PROSPERO: CRD42024534695.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2026) conducted a meta-analysis in Pulmonary arterial hypertension. Sotatercept vs. Placebo was evaluated (p=0.02). Sotatercept was more effective than placebo in treating pulmonary arterial hypertension and demonstrated a fair safety profile (P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: